Table 1.
Characteristics and bias assessment of each study.
| Study (year) | Country | Arms of treatment | Treatment line | Number of patients (osi + beva/osi) | Age, y (osi + beva/osi) | Gender | Follow-up, m | Outcomes reported | Quality assessment | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Experimental arm | Control arm | osi + beva (M/F) | osi (M/F) | ||||||||
| Akamatsu et al. (2021) | Japan | Osimertinib 80 mg qd + bevacizumab (15 mg/kg d1 + q3w) | Osimertinib 80 mg qd | Pretreated | 81 (40/41) | 68 (43–82)/70 (41–82) | 16/24 | 17/24 | osi + beva 16.0/osi 16.2 a | ①, ②, ③, ④ | Cochrane ROB tool: low risk |
| Soo et al. (2022) | Ireland, The Netherlands, Spain, Korea, Singapore, Switzerland | Osimertinib 80 mg qd + bevacizumab (15 mg/kg d1 + q3w) | Osimertinib 80 mg qd | Pretreated | 155 (78/77) | 68 (34–85)/66 (41/83) | 31/47 | 28/49 | osi + beva 32.6/osi 34.5 a | ①, ②, ③, ④ | Cochrane ROB tool: low risk |
| Kenmotsu et al. (2022) | Japan | Osimertinib 80 mg qd + bevacizumab (15 mg/kg d1 + q3w) | Osimertinib 80 mg qd | Treatment-naïve | 122 (61/61) | 67 (59–74)/66 (60–74) | 24/37 | 23/38 | 30.4 (20.1–32.5) b | ①, ②, ③, ④ | Cochrane ROB tool: low risk |
| Feng et al. (2022) | China | Osimertinib 80 mg qd + bevacizumab (15 mg/kg d1 + 7.5 mg/kg q3w) | Osimertinib 80 mg qd | Treatment-naïve | 32 (16/16) | (>60 y/⩽60 y): (9/7)/(10/6) | 12/4 | 10/6 | 12 c | ①, ③, ④ | Cochrane ROB tool: medium risk |
Outcomes: ①, progression-free survival; ②, overall survival; ③, objective response rate; ④, adverse events.
a
Median follow-up time.
b
Median (interquartile range) follow-up time.
c
This study just reported that the follow-up time was 12 months.
beva, bevacizumab; d1, day 1; F, female; M, male; m, month; osi, osimertinib; qd, once daily; q3w, every 3 weeks; RCT, randomized controlled trial; ROB, risk of bias; y, year.